These results indicated that MAPK1, MAPK14, MMP9, NFKBIA, CASP8, and PTGS2 may be the key targets for the pharmacological action of SXXTDP in treating myocardial infarction. The gene discussed is NFKBIA; the disease is myocardial infarction.